Goldman Sachs throws in $37M with Chinese replacement heart valve maker Venus Medtech

The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. They will reportedly be enrolling patients to accomplish this in the early half of the year.

By Nicole Oran on March 25, 2016 9:49 am

money

Chinese replacement heart valve maker Venus Medtech has announced that it received a $37 million investment from Goldman Sachs.

Venus Medtech already has a transcatheter aortic valve replacement (TAVR), the A-Valve, on the market in the People’s Republic and said a pulmonary valve is in clinical trials.

The Power of One: Redefining Healthcare with an AI-Driven Unified Platform

In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.

By David Cohen, Chief Product & Technology Officer, Greenway Health

The A-Valve is the only TAVR device that meets China Food & Drug Administration requirements. The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. They will reportedly be enrolling patients to accomplish this in the early half of the year.

Venus also brought in money from Qiming Venture Partners, Sequoia Capital China and Dinova Venture Capital.

Photo: Flickr user Pictures of Money